AKT1 and breast cancer: Lapatinib, a dual reversible tyrosine kinase inhibitor for HER2 and EGFR receptors block the downstream ERK1/2 and PI3K/AKT signaling pathways thereby inducing the cell-mediated cytoxicity against breast cancer cells [181].